AllDocs -> cancers

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? OCTOBER NOTES Meeting: Tuesday, October 21, 2003 UW Health ? West Clinic Time: 3:30 ? 5:30 PM 451 Junction Road Madison, WI 53717-2656 Program: ?Developments in Stem Cell Transplants? Dr. Mark Juckett Dept. ...

Introduction For many people going on holiday is the highlight of their year.This does not necessarily need to change after a diagnosis of myeloma . If you choose the right holiday for you, plan it well and take a few precautions, you should be able to enjoy holidays both in the UK and abroad. Before you go Letters and medications It often helps to carry a simple written record or doctor's letter, with details about your myeloma and any previous/current treatment. Make a note of the proper names (not trade names) of any medications you are taking with you.You can find out if there are any restrictions on taking certain medications out of the country by contacting the Home Office Drugs Branch (020 7273 3806). If you are on holiday in the UK you can phone NHS Direct (Tel: 0845 4647) for medical advice 24hrs a day.You may also want to carry a 24hr contact number ...

What is thalidomide? Thalidomide is an immunomodulatory drug used in the treatment of myeloma . Immunomodulatory drugs work by affecting the immune system of the body, which is responsible for fighting infection and disease. Thalidomide is not classed as a cytotoxic chemotherapy drug ('chemo'), as it works against myeloma in a different way. Thalidomide has a long and chequered history. It was originally used as a sedative and a treatment for morning sickness 40 years ago. It was withdrawn when it was found to be responsible for birth defects in babies whose mothers took the drug during pregnancy. Since then, it has been cautiously reintroduced as a treatment for several conditions, including leprosy (a chronic infection) and more recently for myeloma . It is now considered to be one of the most significant recent advances in the management of myeloma . How does ...

PROCLAMATION LEUKEMIA LYMPHOMA AND MYELOMA AWARENESS MONTH SEPTEMBER 2003 WHEREAS, blood-related cancers currently afflict more than 670,000 Americans with an estimated 106,000 new cases diagnosed each year; and WHEREAS, leukemia, lymphoma and myeloma will kill an estimated 58,300 people in the United States this year; and WHEREAS, The Leukemia & Lymphoma Society, through voluntary contributions, is dedicated to finding cures for these diseases through research efforts and the support for those that suffer from them; and WHEREAS, the citizens of North Dakota are committed to the eradication of these diseases and support the treatment of those suffering from the diseases; and NOW THEREFORE, as the Governor of the State of North Dakota, I proclaim September 2003 as Leukemia, Lymphoma and Myeloma Awareness Month in the state of North Dakota. /s/ John ...

Pierce Students Collect Pennies For Leukemia, Lymphoma, and Myeloma Patients September 26, 2003, Waterford, Mich . – Students at Pierce Middle School are participating in the Leukemia and Lymphoma Society’s Pennies for Patients Program, which raises funds to find cures for leukemia, lymphoma, and myeloma research and for patients services. Pennies for Patients is one of the Society’s National School and Youth Programs. It has a double benefit in that it allows students to develop compassion and learn the value of helping others while they are working for a good cause. For the third year, pop recording artist Mandy Moore will serve as the Program’s National Honorary Chairperson along with the U.S. National Soccer Players. The Pierce Pennies for Patients Program will run for a three week period from September 29 – October 17. The class collecting the most pennies and other spare change in the school ...

Leukemia, Lymphomas, and Myeloma Mortality in the Vicinity of Nuclear Power Plants and Nuclear Fuel Facilities in Spain 1 Gonzalo Lo´pez-Abente, 2 Nuria Aragone´s, Marina Polla´n, Mari´a Ruiz, and Ana Gandarillas Cancer Epidemiology Unit of the National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain [G. L-A., N. A., M. P., M. R.], and Epidemiology Unit, Madrid Regional Health Authority, 28004 Madrid, Spain [A. G.] Abstract Mortality due to hematological tumors in towns near Spain’s seven nuclear power plants and five nuclear fuel facilities during the period 1975–1993 was ascertained. The study was based on 610 leukemia-, 198 lymphoma-, and 122 myeloma -induced deaths in 489 towns situated within a 30-km radius of such installations. As control areas, we used 477 towns lying within a 50- to 100-km ...

Multiple myeloma Cancer survival, incidence and mortality in NSW 1994–2000 62 The Cancer Council NSW Multiple myeloma • The five-year relative survival from multiple myeloma in NSW between 1994 and 2000 was 34.8% • No Area Health Service was significantly different from the State average in the adjusted relative risk of excess death due to multiple myeloma after shrinking, although significant area variation was detected (p = 0.02) • An additional 97 patients would be expected to survive to five years after diagnosis in NSW if the State average risk was shifted to the 20 th centile of the distribution • There were 1,699 new cases of multiple myeloma in NSW in 1994 to 1998 (962 males and 737 females) and 1,035 deaths (567 males and 468 females) • There were no Area Health Services in which the number of new cases of multiple myeloma was different ...

Page 1 of 4 of Instrument No.73 of 1999. Instrument No.73 of 1999 Revocation of Statement of Principles concerning MULTIPLE MYELOMA and Determination of Statement of Principles concerning MYELOMA ICD-10-AM CODE: C90 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.135 of 1996; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about myeloma and death from myeloma . (b) For the purposes of this Statement of Principles, “ myeloma ” means a form of plasma cell malignancy derived from a single Page 2 ...

Page 1 of 3 of Instrument No.134 of 1996. Instrument No.134 of 1996 REVOKED Revocation and Determination of Statement of Principles concerning MULTIPLE MYELOMA ICD CODE: 203.0 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.1 of 1995; and (b) determines the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about multiple myeloma and death from multiple myeloma . (b) For the purposes of this Statement of Principles, “multiple myeloma ” means a disseminated plasma cell neoplasm of the osseous system, attracting ICD code 203.0, associated with widespread lesions of the skeletal system, hyperglobulinaemia, ...

Page 1 of 3 of Instrument No.135 of 1996. Instrument No.135 of 1996 REVOKED Revocation and Determination of Statement of Principles concerning MULTIPLE MYELOMA ICD CODE: 203.0 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.2 of 1995; and (b) determines the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about multiple myeloma and death from multiple myeloma . (b) For the purposes of this Statement of Principles, “multiple myeloma ” means a disseminated plasma cell neoplasm of the osseous system, attracting ICD code 203.0, associated with widespread lesions of the skeletal system, hyperglobulinaemia, ...

Page 1 of 3 of Instrument No.1 of 1995 Instrument No.1 of 1995 REVOKED Statement of Principles concerning MULTIPLE MYELOMA ICD CODE: 203.0 Veterans’ Entitlements Act 1986 subsection 196 B (2) 1. Being of the view that there is sound medical-scientific evidence that indicates that multiple myeloma and death from multiple myeloma can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(2) of the Veterans’ Entitlements Act 1986 , that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting multiple myeloma or death from multiple myeloma with the circumstances ...

Things in the File Xcytrin demonstrated efficacy in preclinical trials against multiple myeloma cells in a report presented at the July meeting of the American Association for Cancer Research held in Washington D.C. The developer, Pharmacyclics, Inc., indicated they are working in collaboration with Northwestern University. The common name of the drug, motexafin gadolinium would be used as an injection. Some of you may recognize that gadolinium is used during the course of MRI investigations of MM patients to aid in the determination of the activity of the MM. Also of interest, a physicist working at the University of Wisconsin had suggested the potential for combining gadolinium with other drugs as having considerable potential in the treatment of cancer about a year ago. (July 2003) Things in the File (continued) The grapefruit and medications warnings have been making the rounds once more with more research confirming ...

-59- Suggestion: Read the chapter Blood" and "Multiple Myeloma " prior to reading this. WALDENSTROM'S MACROGLOBULINEMIA This disease, like multiple myeloma , is also a monoclonal gammopathy. The abnormal globulin is a large gammaglobulin called IgM. The "M" is a so-called macroglobulin that means that it is about five times the size of other immunoglobulins. The disease is chemically and biologically related to multiple myeloma but is much different in other respects. In multiple myeloma there is usually a great deal of bone disease, but in Waldenstrom's the bones may be normal - without fractures or pain. In Waldenstrom's the liver and spleen are often enlarged, but the kidneys may not be affected as they are in multiple myeloma . Perhaps the most difficult aspect of this disease is that there may be excessive clotting of blood, leading to strokes and clots in important arteries and veins. People with monoclonal ...

Protocol Amendment # 2: September 2, 2002 Stem Cell Transplantation in Multiple Myeloma Rationale Induction phase Tandem high dose Melphalan (200 mg/m²) versus triple intermediate dose Melphalan (100 mg/m²) and stem cell transplantation for induction treatment. High dose Melphalan and stem cell transplantation is standard treatment for patients suitable for this procedure. Recent data from the French Myeloma study group (IFM) showed a significant advantage for tandem transplantation over single transplantation. This study addresses the question, whether triple transplantation with an intermediate dose of Melphalan (100 mg/m²) which is myeloablative, but much better tolerated than 200 mg/m², is equal or superior to tandem transplantation with Melphalan 200mg/m². Maintenance phase Prednisolone/Interferon versus Interferon for Maintenance treatment. Interferon maintenance ...

Protokoll Amendment #1: June 3, 2002 Thalidomide/Dexamethasone vs Melphalan/Prednisone in Multiple Myeloma Rationale Induction phase Thalidomide/Dexamethasone vs Melphalan/Prednisone Thalidomide in combination with Dexamethasone results in significant activity in relapsed/refractory myeloma . This trial evaluates the activity of Thalidomide/ Dexamethasone as first line treatment in comparison to standard Melphalan/Prednisone treatment. Maintenance phase Thalidomide/Interferon-a vs Interferon-a Interferon maintenance treatment has been shown to increase survival by 6 months. The present study aims to evaluate whether the addition of Thalidomide to Interferon maintenance treatment can improve progression free and overall survival.

Stem Cell Transplantation in Multiple Myeloma Contact address For further information please contact: Univ. Prof. Dr. Heinz Ludwig 1st Medical Department and Oncology, Wilhelminenspital 1171 Vienna, Montleartstr. 37 Tel: +43 1 49150 2101; Fax: +43 1 49150 2109 Email: heinz.ludwig@wienkav.at Dr. Judith Schuster Study coordinator 1st Medical Department and Oncology, Wilhelminenspital 1171 Vienna, Montleartstr. 37 Tel: +43 1 49150 2163; Fax: +43 1 49150 2109 Email: judith.schuster@wienkav.at

Protocol Amendment #2 September 2 nd , 2002 Stem Cell Transplantation in Multiple Myeloma Study Design 3 x VAD 1 x IEV + G-CSF (Filgrastim) PBSC-Harvest PBSC-Harvest Day – 2: Melphalan 200 mg/m 2 Day 1, 2, 3, 4, or 5: G-CSF (Filgrastim) RESPONSE EVALUATION RANDOMISATION HD Therapy RESPONSE EVALUATION RANDOMISATION Maintenance Therapy Day 0: PBSC-Transplantation Day – 2: Melphalan 200 mg/m 2 Day 1, 2, 3, 4, or 5: G-CSF (Filgrastim) Day – 2: Melphalan 100 mg/m 2 Day 1, 2, 3, 4, or 5: G-CSF (Filgrastim) Day – 2: Melphalan 100 mg/m 2 Day 1, 2, 3, 4, or 5: G-CSF (Filgrastim) Day – 2: Melphalan 100 ...

Protocol Amendment #2 September 2 nd , 2002 Stem Cell Transplantation in Multiple Myeloma Flow Sheet of Events Induction Maintenance Baseline before start of VAD During VAD and IEV at Day 1 of every Cycle Response Evaluation for 1 st Randomisation Day 1 of every Cycle High Dose Melphalan Response Evaluation for 2 nd Randomisation every 8 weeks during Maintenance Termination or withdrawal visit Informed consent x Med. history/concurrent illnesses x Staging x Vital signs/weight/height x x x x x Physical examination x x x x x Performance status x x x Adverse reactions ...

Thalidomide/Dexamethasone vs Melphalan/Prednisone in Multiple Myeloma Contact address For further information please contact: Univ. Prof. Dr. Heinz Ludwig 1st Medical Department and Oncology, Wilhelminenspital 1171 Vienna, Montleartstr. 37 Tel: +43 1 49150 2101; Fax: +43 1 49150 2109 Email: heinz.ludwig@wienkav.at Dr. Judith Schuster Study coordinator 1st Medical Department and Oncology, Wilhelminenspital 1171 Vienna, Montleartstr. 37 Tel: +43 1 49150 2163; Fax: +43 1 49150 2109 Email: judith.schuster@wienkav.at

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Ann-Hwee Lee*, Neal N. Iwakoshi*, Kenneth C. Anderson †‡ , and Laurie H. Glimcher* †§ *Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115-6017; † Department of Medicine, Harvard Medical School, Boston, MA 02115; and ‡ Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on April 30, 2002. Contributed by Laurie H. Glimcher, June 30, 2003 Novel agents that target the proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, have demonstrated remarkable therapeutic efficacy in multiple my- eloma, ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? JULY NOTES Meeting: Saturday, July 19, 2003 Middleton Public Library 7425 Hubbard Avenue Time: 10:00 AM - NOON Middleton, WI Program: Katherine Bonus, MA, MRED University Hospitals and Clinics ?An Experience/Conversation around Mindfulness Meditation. What are we learning More Information: ...

1 TITLE Microenvironment Factors Do Not Afford Myeloma Cell Lines Protection From Simvastatin. AUTHORS Alla Osadchy, Liat Drucker, Judith Radnay, Hava Shapira, Michael Lishner. INSTITUTION AFFILIATION Oncogenetic Laboratory (AO, LD, ML), Hematology Laboratory (JR, HS) and Department of Internal Medicine (AO, ML), Sapir Medical Center, Meir Hospital, Kfar Sava and Sackler Faculty of Medicine (ML), Tel-Aviv University, Tel-Aviv, Israel. CORRESPONDING AUTHOR Liat Drucker Ph.D., Oncogenetic Laboratory, Sapir Medical Center, Meir Hospital, Kfar Sava, 44281, Israel. Phone: 972-9-7472466; Fax: 972-9-7472369; E-mail: Druckerl@clalit.org.il RUNNING TITLE Cytokines do not protect MM from Sim Page 2 2 ABSTRACT Background : The intensive interactions of myeloma cells (MM) with microenvironmental components of ...

MULTIPLE MYELOMA : UPDATE 2003 BOLZANO – BOZEN October 17-18, 2003 Casa della Cultura-Haus der Kultur “Walther von der Vogelweide” Preliminary Program Page 2 Congress Presidents O. Saurer President of the Local Health Authority P. Coser Head of the Haematology Dept./ Bone Marrow Transplantation Unit Regional Hospital Bolzano-Bozen Organizer Committee Scientific Committee P. Coser - Bolzano-Bozen N. Pescosta - Bolzano-Bozen M. Svaldi - Bolzano-Bozen P. Coser - Bolzano-Bozen H.J. Senn (ESO-D) - St. Gallen A. Costa (ESO) - Milan Haematology / BMT Unit Regional Hospital Bolzano-Bozen Tel. +39 0471 908807 – Fax +39 0471 908703 e-mail: emat@asbz.it Congress Secretary Highstyle Medical Congress Service I-39100 BOLZANO BOZEN Piazza Mazzini 43 ...

myeloma Case Presentation One 55 y/o African-American female presents with c/o shoulder pain. X-ray shows bony destruction of clavicle. Bx in 1985 with plasmacytoma. Treated w/ XRT(4600 rads) and MP X 3 but developed new lytic lesions in L3,L4 vertebral bodies. Treated with VAD x 4 cycles with good response Case one continued In 1988, she was found to have a sternal mass on CXR. XRT with 3000 cGy and Cytoxan (200 mg/m2 q week and prednisone 100 qod for 5 months. Monthly pamidronate Case one continued No events thru 2000. In fall of 2001, she was hospitalized with worsening creatinine and anemia. Skeletal survey negative, bone marrow biopsy with increased plasma cells but <10%. ?Sx due to CRI from HTN Case one continued In spring of 2002, continued to c/o of feeling tired, concerned about ...

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

Brief report Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt The feasibility and efficacy of a combina- tion of thalidomide, cyclophosphamide, etoposide, and dexamethasone were stud- ied in 56 patients with poor-prognosis multiple myeloma . Of 50 patients evalu- able for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive dis- ease (PD), resulting in an objective re- sponse rate ( > MR) of 86.0% (76.7% over- all objective response rate in intent-to- treat analysis; n 56). Subsequent to successful remission induction, 18 pa- tients received autologous or allogeneic stem cell transplantation. The median ...

Brief report Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Bart Barlogie, Raman Desikan, Paul Eddlemon, Trey Spencer, Jerome Zeldis, Nikhil Munshi, Ashrof Badros, Maurizio Zangari, Elias Anaissie, Joshua Epstein, John Shaughnessy, Dan Ayers, Dan Spoon, and Guido Tricot This report of a phase 2 trial of thalido- mide (THAL) (200 mg/d; 200 mg incre- ment every 2 weeks to 800 mg) for 169 patients with advanced myeloma (MM) (abnormal cytogenetics (CG), 67%; prior autotransplant, 76%) extends earlier re- sults in 84 patients. A 25% myeloma pro- tein reduction was obtained in 37% of patients (50% reduction in 30% of pa- tients; near-complete or complete remis- sion in 14%) and was more frequent with low plasma cell labeling index (PCLI) (be- ...

Thalidomide in patients with advanced multiple myeloma : a study of 83 patients ± report of the intergroupe francophone du myeÂlome (IFM) Ibrahim Yakoub-Agha 1 , Michel Attal 1 , Charles Dumontet 1 , VaÂlerie Delannoy 1 , Philippe Moreau 1 , Christian Berthou 1 , Thierney Lamy 1 , Bernard Grosbois 1 , Charly Dauriac 1 , VeÂronique Dorvaux 1 , Jacques-Olivier Bay 1 , Matthieu Monconduit 1 , Jean Luc Harousseau 1 , Corinne Duguet 1 , Alain Duhamel 1 and Thierry Facon* ,1 1 Service des Maladies du Sang, and the laboratoire de biostatistique CERIM, CHRU, Lille, France Background: To evaluate treatment by thalidomide and identify predictive factors of ...

Review article Solitary plasmacytoma of bone and asymptomatic multiple myeloma Meletios A. Dimopoulos, Lia A. Moulopoulos, Alice Maniatis, and Raymond Alexanian Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemo- therapy promptly to reduce the malignant clone. Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere. Such patients usually become free of symptoms after local radiotherapy. In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests. In patients with either solitary plasmacy- toma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression. (Blood. 2000;96:2037-2044) © 2000 by ...

If you are a multiple myeloma patient or caregiver, we would like you to join us as we attempt to help each other. Our meetings are held in London, usually on Wednesday afternoons. Please contact us for times and locations. Watch for meeting notices posted on the bulletin boards at the LRCC or on the LRCC website: www.lrcc.on.ca For more information or to be put in touch with other myeloma patients, please call: Becky Ross (London) (519) 641-7080 bucky03@hotmail.com Jim Barnes (Midwestern Ontario) (519) 887-6163 barnes@scsinternet.com or, to be placed on our mailing list, write: Jim Barnes, 40824 Cardiff Rd., RR#5, Brussels, ON N0G 1H0 Information and support for Multiple Myeloma patients and their caregivers provided through: BI-MONTHLY MEETINGS PEER SUPPORT ...